Biohit Oyj B (BIOBV) - Total Assets
Based on the latest financial reports, Biohit Oyj B (BIOBV) holds total assets worth €19.80 Million EUR (≈ $23.15 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore BIOBV cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Biohit Oyj B - Total Assets Trend (2000–2025)
This chart illustrates how Biohit Oyj B's total assets have evolved over time, based on quarterly financial data. See BIOBV book value for net asset value and shareholders' equity analysis.
Biohit Oyj B - Asset Composition Analysis
Current Asset Composition (December 2025)
Biohit Oyj B's total assets of €19.80 Million consist of 46.0% current assets and 54.0% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €3.50 Million | 17.7% |
| Accounts Receivable | €3.60 Million | 18.2% |
| Inventory | €800.00K | 4.0% |
| Property, Plant & Equipment | €1.90 Million | 9.6% |
| Intangible Assets | €700.00K | 3.5% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2000–2025)
This chart illustrates how Biohit Oyj B's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see BIOBV market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biohit Oyj B's current assets represent 46.0% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 17.7% of total assets in 2025, up from 12.3% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 38.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 18.2% of total assets.
Biohit Oyj B Competitors by Total Assets
Key competitors of Biohit Oyj B based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥5.03 Billion |
|
GN Store Nord
CO:GN
|
Denmark | Dkr29.23 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.52 Billion |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Beijing Succeeder Technology Inc
SHG:688338
|
China | CN¥1.78 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.02 Billion |
|
Stratec SE
XETRA:SBS
|
Germany | €443.38 Million |
Biohit Oyj B - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.53 | 3.67 | 4.28 |
| Quick Ratio | 2.31 | 3.33 | 3.81 |
| Cash Ratio | 0.97 | 1.25 | 0.00 |
| Working Capital | €5.50 Million | €8.00 Million | €6.36 Million |
Biohit Oyj B - Advanced Valuation Insights
This section examines the relationship between Biohit Oyj B's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.89 |
| Latest Market Cap to Assets Ratio | 2.02 |
| Asset Growth Rate (YoY) | 27.7% |
| Total Assets | €19.80 Million |
| Market Capitalization | $39.97 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Biohit Oyj B's assets at a significant premium (2.02x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Biohit Oyj B's assets grew by 27.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Biohit Oyj B (2000–2025)
The table below shows the annual total assets of Biohit Oyj B from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €19.80 Million ≈ $23.15 Million |
+27.74% |
| 2024-12-31 | €15.50 Million ≈ $18.12 Million |
+19.97% |
| 2023-12-31 | €12.92 Million ≈ $15.10 Million |
+17.29% |
| 2022-12-31 | €11.02 Million ≈ $12.88 Million |
+14.58% |
| 2021-12-31 | €9.61 Million ≈ $11.24 Million |
-10.80% |
| 2020-12-31 | €10.78 Million ≈ $12.60 Million |
-37.96% |
| 2019-12-31 | €17.37 Million ≈ $20.31 Million |
-2.88% |
| 2018-12-31 | €17.89 Million ≈ $20.91 Million |
-5.33% |
| 2017-12-31 | €18.89 Million ≈ $22.09 Million |
+45.47% |
| 2016-12-31 | €12.99 Million ≈ $15.19 Million |
+10.75% |
| 2015-12-31 | €11.73 Million ≈ $13.71 Million |
-19.16% |
| 2014-12-31 | €14.51 Million ≈ $16.96 Million |
-48.74% |
| 2013-12-31 | €28.30 Million ≈ $33.09 Million |
-29.26% |
| 2012-12-31 | €40.01 Million ≈ $46.77 Million |
-44.02% |
| 2011-12-31 | €71.47 Million ≈ $83.56 Million |
+143.24% |
| 2010-12-31 | €29.38 Million ≈ $34.35 Million |
+7.24% |
| 2009-12-31 | €27.40 Million ≈ $32.03 Million |
+1.08% |
| 2008-12-31 | €27.11 Million ≈ $31.69 Million |
-0.84% |
| 2007-12-31 | €27.34 Million ≈ $31.96 Million |
+0.07% |
| 2006-12-31 | €27.32 Million ≈ $31.94 Million |
-1.91% |
| 2005-12-31 | €27.85 Million ≈ $32.56 Million |
+22.37% |
| 2004-12-31 | €22.76 Million ≈ $26.61 Million |
+4.04% |
| 2003-12-31 | €21.88 Million ≈ $25.57 Million |
-2.40% |
| 2002-12-31 | €22.41 Million ≈ $26.20 Million |
-10.33% |
| 2001-12-31 | €25.00 Million ≈ $29.22 Million |
-82.93% |
| 2000-12-31 | €146.42 Million ≈ $171.18 Million |
-- |
About Biohit Oyj B
Biohit Oyj, a biotechnology company, manufactures and sells bind acetaldehyde, diagnostic products, and systems for diagnostic analysis for the use of research institutions, healthcare, and industry worldwide. The company's diagnostic tests product includes the GastroPanel Unified test panel for stomach health check; GastroPanel Four-in-One stomach test; GastroSoft software application to assist … Read more